Artivion's Strong Performance in Q2 2024
Artivion, Inc. (ticker: AORT), a prominent medical device company, achieved an impressive 10% year-over-year growth in revenue, reaching $98 million in the second quarter of 2024. The company's adjusted EBITDA surged by 35% compared to the previous year, driven by advancements in key product lines such as On-X, stent grafts, BioGlue, and tissue processing.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
